Global Wilson's Disease Drugs Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Wilson's Disease Drugs Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
Wilson’s disease is also known as progressive lenticular degeneration and hepatolenticular degeneration that causes copper poisoning in the body. Copper is a necessary element for cellular functions; however, excessive copper is extremely toxic and can cause permanent damage to cellular functions of body. Wilson’s disease is caused by excessive deposition of copper in the body. Generally, copper is released into bile from the diet is cleaned out by the liver, flowing out of the body from the gastrointestinal tract. Wilson’s disease occurs due to excessive deposition of copper in the brain, liver, and other tissues of the body. According to the American Association for the Study of Liver Diseases, Wilson’s disease occurs worldwide with prevalence of approximately 30 individuals affected per million.
Wilson's Disease Drugs report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Wilson's Disease Drugs market is projected to reach US$ 307.4 million in 2034, increasing from US$ 204.1 million in 2022, with the CAGR of 5.9% during the period of 2024 to 2034. Demand from Hospitals and Clinic are the major drivers for the industry.
The classification of Wilson’s disease includes Trientine, Penicillamine and others, and the proportion of Trientine in 2019 is about 47%. Penicillamine was the first drug approved for the treatment of Wilson’s disease. Penicillamine is the most successful drug used for the treatment of Wilson’s disease. Wilson’s disease is widely used in Hospital, drugs stores and other field. The most proportion of Wilson’s disease is Drugs Store, and the proportion in 2019 is 51%. North America is the largest consumption place, with a consumption market share nearly 76.93% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 10.51%. Market competition is intense. Bausch Health, Teva, Endo International, Univar Solutions, MSN Laboratories, etc. are the leaders of the industry.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Wilson's Disease Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Kadmon Holdings, Inc.
Merck & Co.
Teva Pharmaceutical Industries Limited
Tsumura & Co.
Valeant Pharmaceuticals International, Inc.
VHB Life Sciences, Inc.
Wilson Therapeutics AB (Alexion)
Segment by Type
Hepatic
Neuropsychiatric
Ophthalmic
Others
Hospitals
Clinic
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Wilson's Disease Drugs market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Wilson's Disease Drugs introduction, etc. Wilson's Disease Drugs Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Wilson's Disease Drugs market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Wilson's Disease Drugs report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Wilson's Disease Drugs market is projected to reach US$ 307.4 million in 2034, increasing from US$ 204.1 million in 2022, with the CAGR of 5.9% during the period of 2024 to 2034. Demand from Hospitals and Clinic are the major drivers for the industry.
The classification of Wilson’s disease includes Trientine, Penicillamine and others, and the proportion of Trientine in 2019 is about 47%. Penicillamine was the first drug approved for the treatment of Wilson’s disease. Penicillamine is the most successful drug used for the treatment of Wilson’s disease. Wilson’s disease is widely used in Hospital, drugs stores and other field. The most proportion of Wilson’s disease is Drugs Store, and the proportion in 2019 is 51%. North America is the largest consumption place, with a consumption market share nearly 76.93% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 10.51%. Market competition is intense. Bausch Health, Teva, Endo International, Univar Solutions, MSN Laboratories, etc. are the leaders of the industry.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Wilson's Disease Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Kadmon Holdings, Inc.
Merck & Co.
Teva Pharmaceutical Industries Limited
Tsumura & Co.
Valeant Pharmaceuticals International, Inc.
VHB Life Sciences, Inc.
Wilson Therapeutics AB (Alexion)
Segment by Type
Hepatic
Neuropsychiatric
Ophthalmic
Others
Segment by Application
Hospitals
Clinic
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Wilson's Disease Drugs market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Wilson's Disease Drugs introduction, etc. Wilson's Disease Drugs Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Wilson's Disease Drugs market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices